LAT1 and ASCT2 Related microRNAs as Potential New Therapeutic Agents against Colorectal Cancer Progression

被引:7
作者
Dias, Francisca [1 ]
Almeida, Cristina [1 ,2 ]
Teixeira, Ana Luisa [1 ]
Morais, Mariana [1 ,3 ]
Medeiros, Rui [1 ,2 ,3 ,4 ,5 ]
机构
[1] Portuguese Oncol Inst Porto IPO Porto, IPO Porto Res Ctr CI POP, Mol Oncol & Viral Pathol Grp, Res Ctr LAB2, E Bdg 1st Floor, P-4200072 Porto, Portugal
[2] Portuguese League Canc Reg Nucleus North LPCC NRN, Res Dept, Estr Circunvalacao 6657, P-4200177 Porto, Portugal
[3] Univ Porto ICBAS UP, Inst Biomed Sci Abel Salazar, Rua Jorge Viterbo Ferreira 228, P-4050513 Porto, Portugal
[4] Univ Porto, Fac Med, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal
[5] Fernando Pessoa Univ UFP, Fac Hlth Sci, Biomed Res Ctr CEBIMED, Praca 9 Abril 349, P-4249004 Porto, Portugal
关键词
colorectal cancer; amino acid transporters; LAT1; ASCT2; miRNAs;
D O I
10.3390/biomedicines9020195
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development and progression of colorectal cancer (CRC) have been associated with genetic and epigenetic alterations and more recently with changes in cell metabolism. Amino acid transporters are key players in tumor development, and it is described that tumor cells upregulate some AA transporters in order to support the increased amino acid (AA) intake to sustain the tumor additional needs for tumor growth and proliferation through the activation of several signaling pathways. LAT1 and ASCT2 are two AA transporters involved in the regulation of the mTOR pathway that has been reported as upregulated in CRC. Some attempts have been made in order to develop therapeutic approaches to target these AA transporters, however none have reached the clinical setting so far. MiRNA-based therapies have been gaining increasing attention from pharmaceutical companies and now several miRNA-based drugs are currently in clinical trials with promising results. In this review we combine a bioinformatic approach with a literature review in order to identify a miRNA profile with the potential to target both LAT1 and ASCT2 with potential to be used as a therapeutic approach against CRC.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 121 条
[1]  
Acunzo Mario, 2015, Adv Biol Regul, V57, P1, DOI 10.1016/j.jbior.2014.09.013
[2]   miRNAs: mediators of ErbB family targeted therapy resistance [J].
Adem, Barbara Filipa ;
Alves Bastos, Nuno Ricardo ;
Dias, Francisca ;
Teixeira, Ana Luisa ;
Medeiros, Rui .
PHARMACOGENOMICS, 2016, 17 (10) :1175-1187
[3]   Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/AKT/mTOR Pathway in Cancer [J].
Agani, Faton ;
Jiang, Bing-Hua .
CURRENT CANCER DRUG TARGETS, 2013, 13 (03) :245-251
[4]   Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism [J].
Ahluwalia, Amrita ;
Jones, Michael K. ;
Szabo, Sandor ;
Tarnawski, Andrzej S. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 437 (04) :515-520
[5]   Colon Cancer: A Clinician's Perspective in 2019 [J].
Ahmed, Monjur .
GASTROENTEROLOGY RESEARCH, 2020, 13 (01) :1-10
[6]  
Alves M.J.F., 2016, MED EXPRESS, V3, DOI [10.5935/MedicalExpress.2016.06.05, DOI 10.5935/MEDICALEXPRESS.2016.06.05]
[7]   Identification of miRNAs correlating with stage and progression of colorectal cancer [J].
Asadi, Milad ;
Talesh, Shoan Taheri ;
Gjerstorff, Morten Frier ;
Shanehbandi, Dariush ;
Baradaran, Behzad ;
Hashemzadeh, Shahriar ;
Zafari, Venus .
COLORECTAL CANCER, 2019, 8 (02)
[8]   Structural biology of solute carrier (SLC) membrane transport proteins [J].
Bai, Xiaoyun ;
Moraes, Trevor F. ;
Reithmeier, Reinhart A. F. .
MOLECULAR MEMBRANE BIOLOGY, 2017, 34 (1-2) :1-32
[9]   Regulation of mTORC1 by amino acids [J].
Bar-Peled, Liron ;
Sabatini, David M. .
TRENDS IN CELL BIOLOGY, 2014, 24 (07) :400-406
[10]   Glutamine transporters in mammalian cells and their functions in physiology and cancer [J].
Bhutia, Yangzom D. ;
Ganapathy, Vadivel .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (10) :2531-2539